A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX208 BRAF V600E Inhibitor Combined With Serplulimab HLX10, Anti-PD-1 Antibody in Advanced NSCLC Patients With BRAF V600E Mutation.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RX 208 (Primary) ; Serplulimab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Henlius Biotech

Most Recent Events

06 Apr 2023 Status changed from not yet recruiting to recruiting.
12 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight